专利检索 ap:"Qinglin PU" 第 1 页

1.

发明申请
NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE 审中-公开

公开(公告)号：US20200230117A1

公开(公告)日：2020-07-23

申请号：US16088873

申请日：2017-04-24

申请人： Phillip M. COWLEY , Meredeth Ann MCGOWAN , Thomas J. BROWN , WISE Alan , Hua ZHOU , Yongxin HAN , Kun LIU , Qinglin PU , Hongjun ZHANG , IOMet Pharma Ltd.

发明人： Phillip M. Cowley , Meredeth Ann McGowan , Thomas J. Brown , Yongxin Han , Kun Liu , Qinglin Pu , Alan Wise , Hongjun Zhang , Hua Zhou

IPC分类号： A61K31/438 , C07D519/00

摘要： Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.

2.

发明公开
IL4I1 INHIBITORS AND METHODS OF USE 审中-公开

公开(公告)号：US20240246937A1

公开(公告)日：2024-07-25

申请号：US18556196

申请日：2022-04-28

申请人： George Madalin GIAMBASU , Andrew M. HAIDLE , Brett A. HOPKINS , James P. JEWELL , Matthew A. LARSEN , Charles A. LESBURG , Ping LIU , Qinglin PU , Sulagna SANYAL , Phieng SILIPHAIVANH , Matthew TUDOR , Catherine M. WHITE , Xin YAN , Lianyun ZHAO , Xiao Mei ZHENG , William P. KAPLAN , Michaelyn Claire LUX , Derun LI , Rebecca JOHNSON , MERCK SHARP & DOHME LLC , MSD R&D (CHINA) CO., LTD.

发明人： George Madalin GIAMBASU , Andrew M. HAIDLE , Brett A. HOPKINS , James P. JEWELL , Matthew A. LARSEN , Charles A. LESBURG , Ping LIU , Qinglin PU , Sulagna SANYAL , Phieng SILIPHAIVANH , Matthew TUDOR , Catherine M. WHITE , Xin YAN , Lianyun ZHAO , Xiao Mei ZHENG , William P. KAPLAN , Michaelyn Claire LUX , Derun LI , Rebecca JOHNSON

IPC分类号： C07D403/06 , C07D401/06 , C07D401/14 , C07D403/10 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/14 , C07D487/04

CPC分类号： C07D403/06 , C07D401/06 , C07D401/14 , C07D403/10 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/14 , C07D487/04

摘要： The invention discloses a synthesizing method of benzimidazole derivant and intermediate, which is characterized by the following: proceeding arylation among aryl halide and primary amine; adopting L-pro as additive, cuprous iodide as catalyst; proceeding molecular arylation coupling reaction for aryl iodide or aryl bromide and primary amine; adopting iodo phenylamine compound and bromophenylamine compound as starting material; synthesizing the material through several-step transformation.

3.

发明公开
IL4I1 INHIBITORS AND METHODS OF USE 审中-公开

公开(公告)号：US20230183214A1

公开(公告)日：2023-06-15

申请号：US17920850

申请日：2021-05-04

申请人： Brandon D. CASH , Wenlang FU , George Madalin GIAMBASU , Andrew M. HAIDLE , Brett A. HOPKINS , Matthew A. LARSEN , Charles A. LESBURG , Ping LIU , Meredeth A. MCGOWAN , Qinglin PU , Sulagna SANYAL , Phieng SILIPHAIVANH , Catherine M. WHITE , Xin YAN , Merck Sharp & Dohme LLC

发明人： Brandon D. CASH , Wenlang FU , George Madalin GIAMBASU , Andrew M. HAIDLE , Brett A. HOPKINS , Matthew A. LARSEN , Charles A. LESBURG , Ping LIU , Meredeth A. MCGOWAN , Qinglin PU , Sulagna SANYAL , Phieng SILIPHAIVANH , Catherine M. WHITE , Xin YAN

IPC分类号： C07D403/10 , C07D413/10 , C07D409/06 , C07D235/26 , C07D403/06 , C07D419/10 , C07D401/14 , C07D401/06 , C07D409/14 , C07D405/06 , C07D401/12 , C07D401/08 , C07D495/04 , C07D417/10

CPC分类号： C07D403/10 , C07D235/26 , C07D401/06 , C07D401/08 , C07D401/12 , C07D401/14 , C07D403/06 , C07D405/06 , C07D409/06 , C07D409/14 , C07D413/10 , C07D417/10 , C07D419/10 , C07D495/04

摘要： Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.

4.

发明授权
Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors 有权

公开(公告)号：US11034661B2

公开(公告)日：2021-06-15

申请号：US16495883

申请日：2018-03-23

申请人： Merck Sharp & Dohme Corp. , Liangqin Guo , Yongxin Han , Kun Liu , Shuwen He , Joseph Kozlowski , Ravi Nargund , Wensheng Yu , Hongjun Zhang , Qinglin Pu , Derun Li , Abdelghani Achab , Guoqing Li

发明人： Liangqin Guo , Yongxin Han , Kun Liu , Shuwen He , Joseph Kozlowski , Ravi Nargund , Wensheng Yu , Hongjun Zhang , Qinglin Pu , Derun Li , Abdelghani Achab , Guoqing Li

IPC分类号： C07D271/08 , C07D413/12

摘要： Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

5.

发明申请
N-(2-CYANO HETEROCYCLYL) PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS 有权
标题翻译： N-（2-氰基杂环基）吡唑并吡喃酮作为甘薯激酶抑制剂

公开(公告)号：US20160272633A1

公开(公告)日：2016-09-22

申请号：US14778052

申请日：2014-03-19

申请人： Christopher DINSMORE , Peter FULLER , David GUERIN , Christopher F. THOMPSON , Qinglin PU , Mark E. SCOTT , Jason David KATZ , Ravi KURUKLASURIYA , Joshua T. CLOSE , Danielle FALCONE , Jason BRUDAKER , Hongbo ZENG , Yunfeng BAI , Jianmin FU , Norman KONG , Yumei LIU , Zhixiang ZHENG , MERCK SHARP & DOHME CORP.

发明人： Christopher Dinsmore , Peter Fuller , David Guerin , Christopher F. Thompson , Qinglin Pu , Mark E. Scott , Jason David Katz , Ravi Kuruklasuriya , Joshua T. Close , Danielle Falcone , Jason Brubaker , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng

IPC分类号： C07D471/04 , C07D519/00

CPC分类号： C07D471/04 , C07D519/00

摘要： Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.

6.

发明申请
GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS 有权
标题翻译：作为JANUS KINASE抑制剂的GEMYALLY取代的氰基乙基吡唑啉吡啶

公开(公告)号：US20160272632A1

公开(公告)日：2016-09-22

申请号：US14778046

申请日：2014-03-19

申请人： Matthew Lloyd CHILDERS , Peter FULLER , David GUERIN , Jason David KATZ , Qinglin PU , Mark E. SCOTT , Christopher E. THOMPSON , Michelle MARTINEZ , Danielle FALCONE , Luis TORRES , Yongqi DENG , Ravi KURUKULASURIYA , Hongbo ZENG , Yunfeng BAI , Norman KONG , Yumei LIU , MERCK SHARP & DOHME CORP.

发明人： Matthew Lloyd Childers , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Michelle Martinez , Danielle Falcone , Luis Torres , Yongqi Deng , Ravi Kurukulasuriya , Hongbo Zeng , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng

IPC分类号： C07D471/04 , C07D519/00

CPC分类号： C07D471/04 , C07D519/00

摘要： The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

摘要翻译： 本发明提供了作为JAK抑制剂的式（I）化合物，因此可用于治疗JAK介导的疾病如类风湿性关节炎，哮喘，COPD和癌症。

7.

发明授权
Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors 有权

公开(公告)号：US10927086B2

公开(公告)日：2021-02-23

申请号：US16483957

申请日：2018-02-19

申请人： Merck Sharp & Dohme Corp. , Kun Liu , Dane Clausen , Liangqin Guo , Yongxin Han , Shuwen He , Joseph Kozlowski , Derun Li , Qinglin Pu , Wensheng Yu , Hongjun Zhang

发明人： Kun Liu , Dane Clausen , Liangqin Guo , Yongxin Han , Shuwen He , Joseph Kozlowski , Derun Li , Qinglin Pu , Wensheng Yu , Hongjun Zhang

IPC分类号： C07D271/08 , C07D413/12

摘要： Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.